Gilead and Kite at ASH 2026
2026-11-20 04:40:13

Gilead and Kite Showcase New Advancements in Cancer Therapies at ASH 2026 Conference

Significant Developments in Cancer Treatments Unveiled



Gilead Sciences and Kite Pharmaceuticals, both headquartered in California, are set to present groundbreaking data at the upcoming American Society of Hematology (ASH) Annual Meeting 2026, which will be held from December 12 to 15 in New Orleans, Louisiana. The duo has announced that they will be sharing 23 presentations during the event, including 7 oral presentations featuring promising advancements in their oncology pipeline.

One of the notable highlights includes the new clinical data emerging from the iMMagine-1 trial, which investigates the safety and efficacy of anitocabtagene autoleucel (anito-cel) for patients with relapsed/refractory multiple myeloma (RRMM). This update showcases a follow-up of over 18 months and sheds light on innovative approaches to treating lymphomas and autoimmune blood disorders.

Dr. Gallia Levy, Senior Vice President and Global Development Lead at Kite, expressed the company’s core belief that those living with blood cancers deserve not just treatments that provide response, but options that may release them from their illness entirely. The data to be presented reflect Kite’s commitment to broader patient benefits across multiple cancer types and its ongoing efforts to advance next-generation cell therapies.

Key Presentations at ASH 2026



1. Expanding Evidence for anito-cel in Multiple Myeloma


Kite will present pivotal findings from the iMMagine-1 trial which targets RRMM as Anitocabtagene autoleucel (anito-cel) is being developed as a CAR T-cell therapy. The study focused on patients with over three lines of prior therapy, assessing various treatment classes for multiple myeloma, and aims to provide valuable insights into the efficacy and long-term sustainability of anito-cel.

  • - Study Design: The iMMagine-1 trial is a multi-center, single-arm, open-label Phase II trial, offering a unique perspective on anito-cel's clinical outcomes over a substantial follow-up duration.

  • - FDA Approval Submission: The trial's data serve as the foundation for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), which is currently under review, aiming for a decision by December 23, 2026.

2. ZUMA-12 Trial Update on Yescarta


Another highlight from Kite will involve the ZUMA-12 trial, a Phase II single-arm clinical trial evaluating Yescarta (axicabtagene ciloleucel) in patients with untreated high-risk large B-cell lymphoma (LBCL). The trial data will demonstrate five-year follow-up results, affirming its role in the first-line treatment setting.

Dr. Levy noted, “Beyond initial responses, we strive to offer therapies that can result in durable remissions amid the complex landscape of blood cancers.” This evolving narrative aligns with Kite's strategy to optimize treatment protocols while ensuring accessibility to outstanding therapies for diverse patient populations.

Real-World Evidence Enhancements


In addition to clinical trial data, Kite and Gilead will reveal findings from real-world evidence, including successful outcomes derived from the DESCAR-T registry in France and various Canadian studies that evaluate the feasibility and safety of outpatient CAR T-cell treatments.

Alongside studies on anito-cel, preliminary clinical experiences with gamgertamig (CM336/OM336), a dual-specific T-cell engager, will also be discussed. This investigational drug is aimed at combating autoimmune conditions, showcasing a broader commitment to addressing inflammation and immune-mediated disorders.

Future Directions


As the landscape of cancer treatment evolves, the data presented at ASH 2026 will not only highlight the tangible progress made in treating complex hematological malignancies but also underline the concerted effort by Gilead and Kite to remain at the forefront of innovation.

The American Society of Hematology’s annual gathering represents a pivotal opportunity for the medical community to come together, sharing insights that can significantly impact patient care worldwide. With ongoing research and collaborative efforts, Gilead and Kite embody a patient-centered approach that prioritizes long-term success in the fight against cancer.

Stay tuned for upcoming summaries of their presentations at ASH 2026 and the promising future of cancer therapies.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.